Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dendritic cell vaccine development using healthy volunteer apheresis samples
NL-OMON55686Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2018
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in cancer, sponsored by Maastricht University Medical Center+. Primary endpoints: Strong in vitro T-cell response and Interferon-gamma production. Started Jul 2018; status: active, not recruiting.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
cancer
Beyond the preview
Go deeper on NL-OMON55686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55686.